Main distributor to Brazil and Latin America for analytical reference substances  |  Welcome! Olá! Hola! Español  |  +1.919.484.7555
You are here: Home /News

News

Survival of the least-fit: Antiviral drug selectively targets the nastiest viruses -- ScienceDaily

An antiviral drug that inhibits a virus’ replication machinery selectively targets the most aggressive viruses, according to new research that looked at the infection of individual cells by a virus and the consequence of antiviral intervention. This new insight into the dynamics of an infection and the mechanism...Read More »


Nanoshells could deliver more chemo with fewer side effects: In vitro study verifies method for remotely triggering release of cancer drugs -- ScienceDaily

Researchers investigating ways to deliver high doses of cancer-killing drugs inside tumors have shown they can use a laser and light-activated gold nanoparticles to remotely trigger the release of approved cancer drugs inside cancer cells in laboratory cultures.

The study by researchers at Rice University and Northwestern University...Read More »


New grant awarded to support leukaemia research in US - Pharmaceutical Technology

Washington University School of Medicine Professor John F DiPersio has received an investigator award of $6m from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to support research, which is aimed at improving therapies for leukaemia.

DiPersio is the Virginia E and Sam J Golman professor of...Read More »


US FDA approves Genentech’s Zelboraf to treat ECD - Pharmaceutical Technology

The US Food and Drug Administration (FDA) has approved Genentech’s Zelboraf (vemurafenib) for the treatment of Erdheim-Chester disease (ECD) with BRAF V600 mutation.

This rare, serious blood disease is characterised by the abnormal multiplication of certain white blood cells called histiocytes, which can invade normal tissues and organs in the body.

FDA...Read More »


Oxford BioDynamics and US firm to advance new treatment for fibrosis - Pharmaceutical Technology

UK-based biotechnology company Oxford BioDynamics (OBD) has collaborated with an undisclosed biopharmaceutical company in the US to advance the discovery and development of new treatments for patients with abnormal wound healing response, leading to fibrosis.

Fibrosis can affect nearly every tissue in the body and if left to progress, the process...Read More »


Boehringer and MiNA to develop new compounds for NASH disease - Pharmaceutical Technology

Boehringer Ingelheim and MiNA Therapeutics have signed an agreement to develop new compounds to treat fibrotic liver diseases such as NASH, based on the latter’s small activating RNA (saRNA) therapeutics platform.

Under the collaboration and licensing agreement, MiNA will receive up to €307m of upfront payment and committed research funding, as...Read More »


Drug-delivering micromotors treat their first bacterial infection in the stomach -- ScienceDaily

Nanoengineers at the University of California San Diego have demonstrated for the first time using micromotors to treat a bacterial infection in the stomach. These tiny vehicles, each about half the width of a human hair, swim rapidly throughout the stomach while neutralizing gastric acid and then release...Read More »


New drug effective against malaria: Promising clinical trial results could give doctors a new tool against drug-resistant strains of malaria parasite -- ScienceDaily

Tulane University researchers have developed a new drug that is effective against non-severe cases of malaria, according to results from an FDA-supervised clinical trial published in the latest issue of The Lancet Infectious Diseases.

The results are significant as public health experts have long warned that the parasite responsible...Read More »


How to reprogram cells in our immune system: The discovery could improve treatments for autoimmune diseases and cancer -- ScienceDaily

When the immune system is imbalanced, either due to overly-active cells or cells that suppress its function, it causes a wide range of diseases, from psoriasis to cancer. By manipulating the function of certain immune cells, called T cells, researchers could help restore the system’s balance and create...Read More »


Novartis’ Rydapt receives approval for two cancer treatments in the EU - Pharmaceutical Technology

The European Commission (EC) has approved Novartis’ Rydapt (midostaurin) for two indications in rare, hard-to-treat cancers.

Rydapt is an oral, targeted treatment that interferes with certain pathways involved in the growth and progression of cancer.

The Novartis therapy is approved for use in combination with standard daunorubicin and cytarabine induction and...Read More »


Older Entries »